Research programme: antibacterials - Vaxart

Drug Profile

Research programme: antibacterials - Vaxart

Alternative Names: Benzothiazole urea based inhibitors -Vaxart; CDI-538 series antibacterials - Prolysis; CDI-936 series antibacterials - Prolysis; GYR-767 series antibacterials - Prolysis; PC-190708; PC-190723

Latest Information Update: 16 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Prolysis
  • Developer Aviragen Therapeutics
  • Class 2 ring heterocyclic compounds; Amides; Small molecules
  • Mechanism of Action Cell division inhibitors; DNA gyrase inhibitors; DNA topoisomerase IV inhibitors; Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Bacterial infections; Clostridium-difficile-infections; Pneumonia; Skin and soft tissue infections; Staphylococcal infections

Most Recent Events

  • 13 Feb 2018 Aviragen Therapeutics has merged with Vaxart forming Vaxart
  • 29 Jan 2018 Discontinued - Preclinical for Bacterial infections in Australia (IV)
  • 29 Jan 2018 Discontinued - Preclinical for Bacterial infections in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top